HeyJaredFDA Watch
FDA Watch is a twice-monthly, national podcast that provides an independent, non-partisan forum for discussing and understanding the latest developments, trends, and issues involving FDA.
- Indexed episodes, last 90 days
- 8
- Latest publication
- Sep 8, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 6, 2026
Latest episodes
Food Safety in the Spotlight (opens the original)
Read excerpt
Wayne chat s with Mason Weeda, Managing Principal at OFW Law and Chair of the firm's FDA Food Practice , and Jessica O'Connell, Partner at Covington and Co-Chair of the firm's Food, Drug, and Device Practice Group . You'll hear their thoughts on FDA's handling of the ongoing Cyclospora outbreak , other food enforcement actions and inspections, potential changes ahead to the GRAS framework, where the agency's fight against synthetic food dyes stands, top-of-mind issues for the rest of 2026 and 20
FDA Legal, Regulatory & Compliance Issues, Part 3: Advertising & Promotion (opens the original)
Read excerpt
In this third part of our series in collaboration with Arnall Golden Grego ry LLP , Wayne chat s with Alan Minsk, Partner, Chair of the Food & Drug practice, and Co-chair of the Life Sciences industry team at AGG; and Laura LaBrie, Associate in the Healthcare and Food & Drug practices at AGG . Together, they discuss recent actions by FDA's Office of Prescription Drug Promotion surrounding direct-to-consumer advertising, AI's role with OPDP enforcement and company promotion and review, and promot
Keeping Up with Medical Device Manufacturing and Digital Health (opens the original)
Read excerpt
Wayne chat s with Cathy Burgess, Partner and Head of the FDA Compliance and Enforcement Team and FDA Practice at Alston & Bird, and Michael Gaba, Food and Drug Vice Chair at Polsinelli . You'll hear their thoughts on what ' s happening these days at CDRH ; key issues for medical device manufactur ers , such as QSMR implementation and enhanced cybersecurity requirements; the evolution of digital health and its impact on clinical decision support technologies and wellness products; what could be n
An Extensive Breakdown of the Pharmaceutical and Biologics Landscape (opens the original)
Read excerpt
Wayne chat s with Daniel Kracov, Partner and Chair of the Life Sciences Industry Group at Arnold & Porter, and Dr. Gayatri Rao, Director at Hyman, Phelps & McNamara . You'll hear their thoughts on Operation TrialBlazer ; what's been happening lately with CBER and CDER; the latest in rare diseases and orphan drugs; developments in cell and gene therapy; the Plausible Mechanism Framework; the situation with China and global drug development; and much more. In our headlines segment, Wayne highlight
FDA Legal, Regulatory & Compliance Issues, Part 2: Customs Regulation & International Trade (opens the original)
Read excerpt
In this second part of our series in collaboration with Arnall Golden Grego ry LLP , Wayne chat s with Luis Arandia Jr., Partner and Co-chair of International Trade at AGG, and Allison Raley, Partner in AGG's Corporate & Finance practice and Chair of the firm's International Compliance & Risk team . Together, they discuss how pharmaceutical and biologics companies should rethink global supply chains in light of the Section 232 tariffs affecting patented pharmaceutical products ; common customs a
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.